2021 starts with a consolidation of IBSA’s position in United States, as the number of products placed on the US market rises to four.
The growth of our overseas company is based on two important pieces of news. Firstly, with effect from 1 January 2021, IBSA Pharma Inc. has bought back the licence to advertise and place on the market Flector brand products. This will translate into an immediate retail price cut for consumers. The diclofenac-based topical product is now the most affordable in the entire US pharmaceutical market.
The second important event is the launch of Licart, the new analgesic patch containing diclofenac and epolamine and the first and only “one-a-day” pharmaceutical product containing nonsteroidal anti-inflammatory drugs (NSAIDs) approved by the FDA, featuring a patented, new-generation patch technology combining two innovative active substance delivery systems. This effectively makes IBSA a leader in the treatment of acute pain associated with minor strains, sprains and bruising.
"We are very excited to have Flector back in our portfolio”, – explained Aldo Donati, Chairman and CEO of IBSA Pharma Inc., “and we are just as proud to be able to offer the market the novel “one-a-day” patch. These two products, together with the highly innovative products for treating hypothyroidism, allow us to provide patients and healthcare professionals with a vast range of unique therapeutic formulations for the treatment of common medical conditions that are frequently encountered in clinical practice”